Intravitreal triamcinolone acetonide for choroidal granuloma in sarcoidosis

Am J Ophthalmol. 2005 Jun;139(6):1116-8. doi: 10.1016/j.ajo.2004.11.055.

Abstract

Purpose: To report the clinical course of intravitreal triamcinolone acetonide on choroidal granuloma secondary to sarcoidosis that was refractory to systemic prednisolone

Design: Interventional case report.

Methods: A 29-year-old Chinese man with sarcoidosis presented with isolated posterior segment involvement in his left eye as retinal periphlebitis, retinal granulomas, and choroidal granuloma. Retinal periphlebitis and retinal granulomas responded well to oral corticosteroid but not the choroidal granuloma. It gradually grew in size and caused a drop in left-eye vision to 20/70. Intravitreal triamcinolone acetonide (4 mg) was injected three times in total.

Results: The choroidal mass began to shrink in size after the second injection and completely regressed after the third. The choroidal granuloma became a scar, with no angiographic leakage. The patient's visual acuity improved and remained stable at 20/40 at the last follow-up, 6 months after the last injection.

Conclusions: Given the encouraging results, further study on intravitreal triamcinolone acetonide for macular and peripapillary choroidal granulomas secondary to systemic sarcoidosis is warranted.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Choroid Diseases / drug therapy*
  • Choroid Diseases / etiology
  • Fluorescein Angiography
  • Glucocorticoids / therapeutic use*
  • Granuloma / drug therapy*
  • Granuloma / etiology
  • Humans
  • Lymphatic Diseases / drug therapy
  • Lymphatic Diseases / etiology
  • Male
  • Retinal Vasculitis / drug therapy
  • Retinal Vasculitis / etiology
  • Sarcoidosis / complications
  • Sarcoidosis / drug therapy*
  • Triamcinolone Acetonide / therapeutic use*
  • Visual Acuity
  • Vitreous Body

Substances

  • Glucocorticoids
  • Triamcinolone Acetonide